Pioneering the Future of
Reproductive Medicine
with EV Technology
EXORPHIA is a biotechnology company with its own EV (extracellular vesicle) manufacturing and quality platform.
Building on this platform, we develop next-generation IVF technologies
as our core business in assisted reproductive technology (ART).
Building on this platform, we develop next-generation IVF technologies
as our core business in assisted reproductive technology (ART).
News
- 2026.08.05NEWS RELEASEScheduled Website Maintenance (August 7)
-
2026.06.01NEWS RELEASEResearch presented at the 67th Annual Meeting of the Japan Society for Ova Research (JSOR)
-Latest R&D findings in reproductive medicine – -
2026.03.13NEWS RELEASESelected for the Tokyo Metropolitan Government’s FY2025 Strategic Innovation Promotion Program
– Accelerating development of next-generation IVF technology – -
2026.03.04NEWS RELEASEEXORPHIA joins the Fertility Technology Council
– Applying biotechnology to bottlenecks in ART – -
2025.10.17NEWS RELEASEEXORPHIA researcher Izumi Kaneko receives the Yanagimachi Ryuzo Prize
– Best presentation award, 28th Annual Meeting of the Japan Society of Assisted Reproduction (JSAR) –